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Description of the evidence elaboration method
The members of the Comissão de Espondiloartrites da Sociedade 
Brasileira de Reumatologia (Commission on Spondyloarthritis 
of the Brazilian Society of Rheumatology, SBR) 2010-2012 took 
part in the Evidence Preparation Course given by the Associa-
ção Médica Brasileira (Brazilian Medical Association, AMB) in São 
Paulo in the fi rst semester of 2011. The questions were fi nally 
concluded at a meeting of the Commission on Spondyloarthri-
tis held on 15 October 2011 in Florianópolis (SC, Brazil), dur-
ing the 18th Southern Cone Rheumatology Meeting and were 
later approved by all the coordinators of the Brazilian Spon-
dyloarthritis Registry. The 15 clinical questions considered to 
be relevant were structured using the P.I.C.O. method (patient; 
intervention or indicator; comparison; outcome). The litera-
ture search was conducted by searching the databases MED-
LINE, EMBASE, SciElo/Lilacs, and the Cochrane Library through 
February, 2012 (Appendix). Critical assessment of the evidence 
in the selected articles was performed using the Jadad score. 
Next, the answers to the questions included in the Recommen-
dations were elaborated, and all the selected references exhibit 
the corresponding grade of recommendation and strength of 
scientifi c evidence. The references were updated through Au-
gust, 2012, entered into a single fi le by the coordinator, and sent 
to the co-authors in two successive rounds for preparation of 
the fi nal version. 
Grades of recommendation and strength of evidence
A: Most consistent experimental and observational studies.
B: Less consistent experimental and observational studies.
C: Case reports (uncontrolled studies).
D: Opinion that is not substantiated by critical evaluation, 
based on consensus, physiological studies or animal 
models.
☆ Study with the seal of the Brazilian Society of Rheumatology. 
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Objective
To establish recommendations for the management (criteria 
for classifi cation and clinical assessment) and treatment of 
psoriatic arthritis.
Introduction
Skin psoriasis is a relatively frequent condition that affects 
1-3% of the overall population. Psoriatic arthritis is the most 
common of the non-skin manifestations of psoriasis and af-
fects 8-42% of patients. Joint condition (arthritis, enthesitis, 
and/or dactylitis) may be associated with signifi cant functional 
limitation of affected individuals. Therefore, early diagnosis is 
of paramount importance in permitting the establishment of 
effi cient therapeutic strategies. Recently, the formulation of the 
Classifi cation Criteria for Psoriatic Arthritis (CASPAR) criteria1(B) 
has made the characterisation of patients with psoriatic arthri-
tis easier and more comprehensive, while the development of 
novel therapies has improved the effi cacy of treatment. Access 
to information about diagnostic and therapeutic advances re-
lated to psoriatic arthritis is indispensable to achieving a better 
and more thorough understanding of this disease.
1. What are the criteria on the basis of which 
an individual is considered to have psoriatic 
arthritis?
There are several classifi cation criteria for psoriatic arthritis; 
these are described below.
a) Moll & Wright criteria: psoriasis or history of psoriasis or 
nail disease, negative rheumatoid factor (RF), and one of 
the following clinical conditions: asymmetric oligoarticular 
arthritis; polyarticular arthritis; distal interphalangeal pre-
dominance; predominant spondylitis; mutilating arthritis. 
b) Bennett criteria: psoriasis of the skin or nails, pain and 
edema of soft tissue, and/or reduced mobility of at least 
one joint in addition to six of the following items: distal 
interphalangeal arthritis; asymmetric arthritis; absence of 
subcutaneous nodules; negative RF; infl ammatory syno-
vial fl uid; synovial hypertrophy on biopsy; erosive arthritis 
affecting small joints; sacroiliitis; syndesmophytes; para-
vertebral ossifi cation. 
c) Vasey & Espinoza criteria: psoriasis or history of psoriasis 
or nail disease and one of the following items: peripheral 
distal phalangeal involvement; dactylitis; asymmetric ar-
thritis; osteolysis; erosive arthritis; periostitis; ankylosis; 
central backache or stiffness; symmetric sacroiliitis. 
d) Fournié criteria (score of 11 points): psoriasis (6 points), 
history of psoriasis (3 points), distal interphalangeal ar-
thritis (3 points), cervical or thoracic spinal infl ammation 
(3 points), asymmetric arthritis (1 point), pain (2 points), 
HLA-B16 or B17 (6 points), negative RF (4 points), erosion of 
distal phalanges, osteolysis, ankylosis, bone formation, or 
tuft erosion (5 points).
e) European Spondyloarthropathy Study Group (ESSG) crite-
ria: infl ammatory pain in the back or synovitis and psoria-
sis or family history of psoriasis.
f) CASPAR criteria: confi rmed infl ammatory joint disease 
(joints, spine, or entheses) and at least three of the follow-
ing: current psoriasis; personal or family history of psoria-
sis; dactylitis; juxta-articular bone formation (hands and 
feet); negative RF; psoriatic nail dystrophy1(B). The sensi-
tivity and specifi city of the CASPAR criteria are 99.7% and 
99.1%, respectively2(B).
According to the CASPAR criteria, the clinical character-
istics of psoriasis patients included psoriasis in 100% of pa-
tients, psoriatic nail dystrophy in 28.5%, negative RF in 77.1%, 
dactylitis in 34.2%, and juxta-articular bone formation in 
34.2%. The most common clinical forms of psoriasis include 
those with predominance of peripheral joint infl ammation 
(81.2%) and those with polyarticular involvement (47.8%)1(B).
In patients with psoriatic arthritis, the Bennett criteria 
were positive in 10.2% of the cases, while Moll & Wright’s cri-
teria were satisfi ed in 30.7% of cases, ESSG’s in 43.5%, Vasey 
& Espinoza’s in 46.1%, Fournié’s in 79.4%, and CASPAR in 
89.7%3(B). 
The predominant clinical criteria upon diagnosis of pa-
tients with psoriatic arthritis and their corresponding relative 
prevalence, sensitivity, and specifi city were: synovitis (151%, 
51%, and 100%), enthesopathy (140%, 40%, and 100%), dactyli-
tis (120%, 20%, and 100%), family history (118%, 51%, and 67%), 
infl ammatory lumbar pain (113%, 13%, and 100%), and alter-
nating buttock pain (111%, 13%, and 98%)4(B). 
The domain most frequently investigated in the assess-
ment of patients with psoriatic arthritis is the skin [Psoriasis 
Area Severity Index (PASI) and Physicians’ Global Assessment 
of Psoriasis (PGAP)], followed by the joints (number of affected 
joints, distal interphalangeal involvement, and the presence 
or absence of symmetric polyarthritis). Other clinical features 
taken into consideration include enthesitis [presence of pain, 
Maastricht Ankylosing Spondylitis Enthesitis Score (MASES)], 
dactylitis [number of affected fi ngers and Infl iximab Multina-
tional Psoriatic Arthritis Controlled Trial Index for Dactylitis 
(IMPACT 1)], and nail disease [Nail Psoriasis Severity Index 
(NAPSI)]5(B).
Recommendation 1
The CASPAR classifi cation criteria are the most widely used 
criteria for psoriatic arthritis. 
2. Are there correlations among skin, nail, and 
joint disease activity in psoriatic arthritis?
In patients with psoriatic arthritis, skin disease antedated 
arthritis in 60% of cases and occurred concomitantly in the 
same year in 31%, while arthritis antedated skin manifesta-
tions in 9%. There was signifi cant correlation between the de-
gree of skin involvement (PASI) and Schober’s test. Deformed 
joints were associated with high PASI scores. The score for 
scalp involvement exhibited a positive correlation with the 
number of affected joints (deformities, dactylitis, and distal 
interphalangeal involvement). Similarly, there was a positive 
correlation between nail and joint effects and between nail 
effects and the number of affected joints6(B).
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Nail thickening with or without surface irregularities oc-
curred in 95.7% of cases of psoriatic arthritis. Diagnosis of nail 
involvement using magnetic resonance imaging was more 
common in patients with clinical signs of nail disease. Simi-
larly, patients with distal interphalangeal abnormalities more 
often exhibited clinical signs of nail disease, showing a risk 
that was increased by 49.2%7(B). 
Nail involvement occurred signifi cantly more often in pa-
tients with psoriatic arthritis than in patients with psoriasis 
alone (59% greater risk), but there was no correlation between 
patterns of skin and nail involvement8(B). The area of affected 
skin was four times greater in patients with psoriasis with-
out arthritis (9.8%) than in patients with psoriatic arthritis 
(2.5%)9(B).
Recommendation 2
There is variable correlation between the intensity of skin 
manifestations and joint involvement in psoriatic arthritis. 
Nail alterations occur more frequently in patients with pso-
riatic arthritis.
3. What are the comorbidities most often 
associated with psoriatic arthritis?
Compared to patients with psoriasis alone, patients with pso-
riatic arthritis exhibited 4.9% increased risk of cardiovascular 
disease (number needed to harm (NNH) = 20), 17.5% increased 
risk of hypertension (NNH: 6), 6.2% increased risk of hyper-
lipidaemia (NNH: 16), 5.3% increased risk of type 2 diabetes 
(NNH: 19), 3.5% increased risk of obesity (NNH: 32), 4.3% in-
creased risk of respiratory disease (NNH: 24), 6.7% increased 
risk of gastrointestinal disease (NNH: 14), 5.7% increased risk 
of neurological disease (NNH: 19), 11.4% increased risk of de-
pression or anxiety (NNH: 9), and 4.7% increased risk of can-
cer (NNH: 21)10(B).
Patients with psoriatic arthritis exhibited 79% increased 
relative risk of stroke, acute myocardial infarction, and car-
diovascular death, similar to patients with psoriasis without 
arthritis11(B). 
Patients with established psoriatic arthritis exhibited 22.9-
49.3% increased risk of hypertension (NNH: 2-5), 2.2-5.3% in-
creased risk of diabetes (NNH: 19-45), 7.4-8.1% increased risk 
of Crohn’s disease (NNH: 12-14), and 6.4-11.8% increased risk 
of chronic obstructive pulmonary disease (NNH: 8-15). Pa-
tients in the early stages of psoriatic arthritis exhibited 22.8-
26.6% increased risk of hypertension (NNH: 4)12(B). These pa-
tients also show 22.9% increased risk of metabolic syndrome 
(NNH: 4)13(B) as well as increased risk of atherosclerosis and 
peripheral vascular disease14(B).
Patients with psoriatic arthritis exhibited 2-17% increased 
risk of thyroid-stimulating hormone (TSH) levels > 3.5 μU/
mL, 12-16% increased risk of antithyroid peroxidase anti-
body (AbTPO) levels > 100 IU/mL, and 15-20% increased risk 
of thyroid autoimmunity (positive antithyroglobulin antibody 
– AbTg+, or AbTPO+)15(B).
Uni- or bilateral uveitis was found in 25% and 37.5% of pa-
tients with psoriatic arthritis, respectively, with similar dis-
tribution of the anterior and posterior forms; on average, in-
sidious progression occurred in 19% of cases nine years after 
diagnosis of arthritis16(B).
Recommendation 3
Psoriatic arthritis is associated with increased risk of some 
comorbidities, including cardiovascular diseases, type 2 dia-
betes, gastrointestinal, respiratory and neuropsychiatric dis-
eases, hypothyroidism, and uveitis. 
4. What is the evidence regarding the use of 
corticosteroids in patients with psoriatic arthritis?
Glucocorticoids may be used as adjuvant therapy in the 
localised forms of the disease (oligoarticular, enthesitis, 
dactylitis)17(D). Corticosteroid (methylprednisolone) injections 
in doses varying from 5-80 mg can be used in cases of joint in-
fl ammation or injury, including in the interphalangeal region 
(44%), knees (21%), and coxofemoral joints (9.4%). The odds 
of achieving clinical response in three and six months were 
41.6% and 51.5%, respectively. Approximately 25.5% of the 
joints that responded at three months exhibited relapse18(B).
The use of systemic corticosteroids in patients with pso-
riatic arthritis has not been consistently investigated. In fact, 
expert opinion contraindicates the use of systemic corticoids 
in psoriasis, recommending that they be restricted to special 
situations and only used for short periods of time. Despite 
those considerations, systemic corticoids were prescribed 
to 24.4-30% of patients with psoriatic arthritis while closely 
monitoring the possible worsening of the skin condition19(B). 
Long-term use of glucocorticoids may induce resistance, for 
example, in cases where psoriasis is controlled by methotrex-
ate, in addition to its association with adverse events such 
as development of osteoporosis, reduced glucose tolerance, 
and increased incidence of infections. Discontinuation of cor-
ticoids has been associated with the occurrence of pustular 
psoriasis20(C).
Used in 24.4% of patients with psoriatic arthritis, the most 
frequently employed systemic corticosteroid was methylpred-
nisolone (65.9%), followed by defl azacort (22.8%), prednisone 
(4.4%), betamethasone (2.3%), and dexamethasone (2.3%). The 
average daily dose of methylprednisolone was 4.5 ± 1.4 mg21(C).
Recommendation 4
Intra-articular corticosteroids may represent a therapeutic 
option in cases of mono or oligoarticular joint involvement in 
psoriatic arthritis. Systemic use of corticosteroids is not rec-
ommended due to a lack of evidence regarding their effi cacy, 
a risk of severe adverse events, and relapse of skin psoriasis 
upon discontinuation. 
5. What is the evidence regarding the use of non-
steroidal anti-infl ammatory drugs (NSAIDs) in 
patients with psoriatic arthritis?
Indomethacin at a dose of 50 mg/day elicited clinical response 
(improvement of pain, movement limitation, and stiffness) in 
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62% of patients with psoriatic arthritis followed up for eight 
weeks; its use was associated with adverse effects such as 
vertigo, nausea, and headache22(B).
A comparison of indomethacin with diclofenac at a dose of 
75 mg/day in patients with psoriatic arthritis showed a non-
signifi cant clinical response after eight weeks to both inves-
tigated drugs and no differences between them in relation to 
adverse events23(B).
The anti-infl ammatory agent nimesulide at doses of 200 
and 400 mg/day induced the following benefi ts in patients 
with psoriatic arthritis: reduction in pain score, reduction in 
scores for swelling and morning stiffness, and reduced use 
of analgesics, without signifi cant increase in the number of 
adverse events24(B).
Treatment of patients with psoriatic arthritis with celecox-
ib at doses of 200 and 400 mg over two weeks increased the 
rates of clinical response measured by the American College of 
Rheumatology Responders Index 20% (ACR20) by 21% [number 
needed to treat (NNT): 5] and 11% (NNT: 9), respectively. Howev-
er, there was no difference in response between patients treat-
ed with celecoxib and untreated patients after 12 weeks25(A).
Recommendation 5
Treatment with non-steroidal anti-infl ammatory drugs rep-
resents an option for short-term symptomatic treatment of 
psoriatic arthritis. 
6. What is the evidence regarding the use of the 
conventional drugs methotrexate, cyclosporine, 
lefl unomide, and sulfasalazine in patients with 
psoriatic arthritis?
Methotrexate
Methotrexate at a dose of 2-5 mg every 12 hours, given in three 
consecutive doses per week, did not improve swelling, morning 
stiffness, pain, strength, or joint involvement in patients with 
psoriatic arthritis over 12 weeks compared to those who did 
not use methotrexate; however, it reduced the physician-as-
sessed severity scores. Its use was associated with gastrointes-
tinal disorders, stomatitis, and increased bilirubin levels26(B).
After 24 months of follow up, no difference was found in 
the clinical responses (≥ 40% improvement in actively infl amed 
joint count) of patients with psoriatic arthritis treated with 5-7.5 
mg methotrexate per week and those using NSAIDs. Radiologi-
cal assessment found a non-signifi cant increase of 16% in joint 
damage scores in the patients treated with methotrexate27(B).
Association of methotrexate with NSAIDs since the begin-
ning of treatment or in the second trimester of a six-month pe-
riod of treatment of patients with psoriatic arthritis was ben-
efi cial relative to the activity of the disease as measured by (1) 
swollen or stiff joint counts; (2) global assessment by patients 
or doctors; and (3) pain visual analogue scale (VAS); there was 
no difference between the two regimens28(B).
A comparison of six-month treatment with methotrexate 
in patients with psoriatic arthritis and rheumatoid arthritis 
found better results in the latter. However, in the beginning 
of treatment, the patients with psoriatic arthritis exhibited 
reduction in the number of affected joints, reduction of pain 
(VAS), reduction in the global assessment of disease activity 
by both patients and doctors, improved quality of life [Modi-
fi ed Health Assessment Questionnaire (MHAQ) and Medical 
Outcomes Study 36-item Short-Form Health Survey (SF-36)]. 
Nevertheless, relative to the disease activity score (DAS), the 
number of patients with psoriatic arthritis with DAS ≥ 2.6 and 
≥ 3.2 increased 17% and 29%, respectively29(B).
The adverse events most frequently associated with the use 
of methotrexate were nausea, photosensitisation, and aphthae 
(leading to discontinuation) and increased liver enzyme levels 
(35%)30,31(B).
Cyclosporine
A comparison of cyclosporine (3 mg/kg/day) and methotrex-
ate (three consecutive 2.5-mg doses every 12 hours per week) 
in the treatment of psoriatic arthritis showed that after 12 
months both resulted in improvement in joint swelling and 
pain, morning stiffness, and strength and in reduced activity 
of disease as assessed by patients and doctors, without dif-
ference between the treatments. Methotrexate increased liver 
enzyme levels, while cyclosporine did not32(B).
Compared to sulfasalazine (2 g/day) combined with symp-
tomatic medications or symptomatic medication alone 
(NSAIDs, analgesics, and/or prednisolone) over six months, 
cyclosporine (3 mg/kg/day) induced better results relative to 
pain relief and reduction in the number of affected joints. 
There was 34% reduction of the disease activity according to 
the patients’ global assessment, 24% reduction according to 
the doctors’ assessment, and better scores on the Arthritis 
Impact Measurement Scale and Spondylitis Functional In-
dex were achieved after treatment. Compared to symptom-
atic treatment, cyclosporine increased the number of patients 
who reached ACR50 and ACR70 by 22% and 24%, respectively. 
Adverse events included deterioration of the function, gastro-
intestinal and neurological disorders, and hypertension33(A).
In patients with psoriatic arthritis and incomplete re-
sponse to methotrexate, the use of cyclosporine (2.5 mg/kg/
day) over 48 weeks reduced the risk of joint involvement by 
36% (NNT: 3), as well as reducing PASI and the number of 
swollen joints. The pain score did not change signifi cantly, but 
the number of adverse events (nausea, headache, paresthesia, 
and burning sensation) increased34(B).
A comparison of adalimumab treatment (40 mg on al-
ternate weeks), treatment with cyclosporine (2.5-3.75 mg/
kg/day) and treatment with a combination of both drugs in 
patients with psoriatic arthritis showed that use of the com-
bined drugs increased the response (Psoriatic Arthritis Re-
sponse Criteria) by 30% compared with cyclosporine alone 
(NNT: 3) and that it increased the number of patients who 
reached ACR50 by 51% (NNT: 2). Use of the combination regi-
men also improved the patients’ scores on the Health Assess-
ment Questionnaire Disability Index and reduced the use of 
NSAIDs and corticosteroids by 51% (NNT: 2)35(B). 
Lefl unomide
Use of lefl unomide (100 mg/day for three days followed by 20 
mg/day) by patients with psoriatic arthritis improved responses 
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in all the Psoriatic Arthritis Response Criteria (PsARC) domains 
(joint pain, degree of swelling, and global assessment) by 29.2% 
(NNT: 3). It also increased the number of patients who reached 
ACR20 by 16.3% (NNT: 6) and improved the quality of life as mea-
sured by the Health Assessment Questionnaire (HAQ)36(A).
The rate of treatment discontinuation due to adverse events 
was greater with lefl unomide (29.2%) than with methotrex-
ate (10.8%), although the difference was not signifi cant. The 
incidence of adverse events associated with lefl unomide (38.7 
events per 100 patients/year) was higher than for methotrex-
ate (14.3 events per 100/year); lefl unomide was also found to 
increase liver enzyme levels37(B). During 24 months of follow 
up, 33.3% of the patients discontinued treatment, 11.1% due 
to lack of effi cacy and 23.3% due to the occurrence of adverse 
events38(B).
Sulfasalazine
After 24 weeks, patients with psoriatic arthritis who were treat-
ed with sulfasalazine (40 mg/kg/day) did not exhibit differences 
in pain, morning stiffness, global assessment of disease activity, 
or index of discontinuation compared to untreated patients39(B).
No benefi ts were found relative to pain, strength, number of 
affected joints, or joint swelling after 12 weeks of treatment with 
sulfasalazine (500 mg/day). The only measures that showed im-
provement were the patients’ and doctors’ global assessment of 
disease activity and the duration of morning stiffness40(B).
Treatment of psoriatic arthritis patients with sulfasalazine 
(2.0 g/day) over 24 weeks improved pain as assessed on VAS, but 
the treated patients did not differ from untreated patients with 
respect to morning stiffness, reduction in the number of affected 
joints, or score on the Ritchie articular index. The most frequent 
adverse events associated with sulfasalazine were nausea, gas-
trointestinal disorders, headache, skin reactions, and increased 
liver enzyme and creatinine levels41(B).
Recommendation 6
The effi cacy of methotrexate in the treatment of psoriatic ar-
thritis is controversial; although this drug is sometimes used 
in combination with NSAIDs, its use should be carefully mon-
itored due to the possibility of hepatotoxicity. 
Cyclosporine is an effi cacious option for the treatment of 
psoriatic arthritis, and its results may be potentiated by com-
bination with adalimumab.
Lefl unomide may be used in the treatment of psoriatic ar-
thritis but should be carefully monitored due to its hepato-
toxicity. 
Sulfasalazine can be used in psoriatic arthritis to afford 
pain relief. 
7. What are the indications for the use of anti-
tumour necrosis factor (TNF) agents in psoriatic 
arthritis?
Infl iximab
In patients who have had psoriatic arthritis for more than six 
months, therapeutic failure of disease-modifying anti-rheu-
matic drugs (DMARDs), peripheral polyarthritis, or morning 
stiffness lasting longer than 45 minutes, infl iximab at a dose 
of 5 mg/kg/day at weeks 0, 2, 6, and 14 may improve ACR20, 
ACR50, and ACR70 responses42(A).
In patients who had psoriatic arthritis for more than six 
months, therapeutic failure with DMARDs or NSAIDs, pe-
ripheral polyarthritis, morning stiffness lasting longer than 
45 minutes, or plaque psoriasis and who were free of tuber-
culosis, infections, cancer, and heart failure, treatment with 
infl iximab at a dose of 5 mg/kg/day on weeks 0, 2, 6, 14, and 
22, combined or not with methotrexate, affected their clinical 
progression43(A).
Etanercept
Treatment of patients with active psoriatic arthritis and 
inadequate response to NSAIDs may be performed with 
etanercept in 25 mg doses twice per week subcutaneously 
(SC) over 12 or 24 weeks, combined or not combined with 
methotrexate44,45(A).
Adalimumab
In adult patients with moderate to severe active psoriatic ar-
thritis (at least three swollen and painful joints) or who have 
psoriatic skin lesions or a history of psoriasis, inadequate re-
sponse or tolerance to NSAIDs, who are using or not using 
methotrexate, and who are without history of neurological 
symptoms suggestive of demyelinating disease, without his-
tory of active tuberculosis or listeriosis and without presence 
of severe infections, the use of 40 mg (SC) adalimumab on al-
ternate weeks over 24 weeks of follow up can be assessed in 
relation to the ACR20 response at week 12 and the change in 
the Sharp score of structural damage on hand and foot x-rays 
at week 24. Other outcomes that may be assessed are ACR50, 
ACR70, response as measured by PsARC, HAQ-Disability Index 
(DI), SF-36 at weeks 12 and 24, and the occurrence of adverse 
events46(B).
In adult patients with moderate to severe active psoriat-
ic arthritis (at least three swollen and painful joints) or who 
have chronic plaque psoriatic skin lesions or inadequate re-
sponse to DMARDs in combination or without combination 
with methotrexate, who are without history of use of anti-TNF 
drugs or corticoids in the past four weeks, who are not using 
topical agents against psoriasis or phototherapy, who have not 
used alefacept or siplizumab or any other biological agent in 
the past 12 weeks, who are without infection or history of tu-
berculosis, heart, kidney, neurological, psychiatric, endocrine, 
metabolic, or liver disease, and who are without symptoms of 
demyelination or cancer, treatment with 40 mg adalimumab 
on alternate weeks over 12 weeks may have an effect on the 
response measured by ACR20, ACR50, or ACR 7047(A).
Golimumab
In patients with active psoriatic arthritis and inadequate 
response to DMARDs or NSAIDs who are using or not using 
methotrexate, treatment with 50 or 100 mg golimumab every 
four weeks over a period of 20 weeks may increase the ACR20 
response48(A).
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Recommendation 7
Treatment with anti-TNF drugs (infl iximab, etanercept, adalim-
umab, golimumab) is indicated in adult patients who have had 
moderate to severe active psoriatic arthritis (at least three swol-
len and painful joints) for more than six months and in those 
with chronic plaque psoriatic skin lesions or history of psoriasis 
and inadequate response or intolerance to NSAIDs or DMARDs 
over three months, combined or not with methotrexate.
8. Does the effi cacy of various anti-TNF drugs 
differ in patients with psoriatic arthritis?
Patients with psoriatic arthritis and indication for treatment 
with anti-TNF drugs who were comparatively treated with in-
fl iximab (INF) at a dose of 5 mg/kg/day every 6-8 weeks, with 
25 mg etanercept (ETN) twice per week, or with 40 mg adali-
mumab (ADA) on alternate weeks and were followed up over 
three months to one year exhibited ACR20 response rates of 
72%, 70%, and 75% with ETN, ADA, and INF, respectively. No 
patient exhibited full remission (absence of clinically affected 
joints) after one year49(B). Table 1 shows the comparison of 
NNT in various anti-TNF drugs used in the treatment of PA.
Infl iximab
In patients with psoriatic arthritis for more than six months, 
therapeutic failure with DMARDs, peripheral polyarthritis, 
and morning stiffness lasting more than 45 minutes, treat-
ment with infl iximab at 5 mg/kg at weeks 0, 2, 6, and 14 in-
creased the ACR20 response rates by 55% (NNT: 2), ACR50 by 
46% (NNT: 2), and ACR70 by 29% (NNT: 3). The patients’ re-
sponses were also measured as scores in the HAQ. The PsARC 
response exhibited a 54% increase (NNT: 2), the dactylitis 
score improved by 56% (NNT: 2), enthesitis decreased by 17% 
(NNT: 6), and DAS28 improved by 43.2% (NNT: 2)42(A). 
In patients with psoriatic arthritis for more than six 
months, therapeutic failure with DMARDs or NSAIDs, pe-
ripheral polyarthritis, morning stiffness lasting more than 
45 minutes, and plaque psoriasis who were without tuber-
culosis, infections, cancer, or heart failure, treatment with 
infl iximab at 5 mg/kg on weeks 0, 2, 6, 14, and 22 showed the 
following:
• A greater proportion of patients achieved ACR20 response 
at week 14 (47%) – NNT: 2 and at week 24 (38%) – NNT: 2. At 
week 14, 33% of the patients treated with infl iximab exhib-
ited a greater ACR50 response (NNT: 3), and 14% reached 
ACR70 (NNT: 7)43(A);
• At week 14, 50% of the patients treated with infl iximab ex-
hibited improvement as measured by PsARC (NNT: 2); at 
week 24, this was 38% (NNT: 3)43(A);
• The risk of dactylitis decreased by 12% (NNT: 8) and 22% 
(NNT: 5) at weeks 14 and 24, respectively. Enthesopathy de-
creased by 12% (NNT: 8) and 17% (NNT: 6) at weeks 14 and 
24, respectively43(A);
• The proportion of patients who exhibited clinical response 
as measured by HAQ increased 40% (NNT: 3) and 32% (NNT: 
3) at weeks 14 and 24, respectively43(A);
• These results persisted at week 5450(B);
After two years of follow up, the ACR20, ACR50, and ACR70 
response rates were 45%, 45%, and 35%, respectively51(B).
The impact of treatment with infl iximab on work capacity 
assessed at week 14 showed a 58.3% increase in productivity 
(NNT: 2), an 11.5-20% increase in the employment rate (NNT: 
5-8), and a reduction in the number of lost work days52(A).
Etanercept
Treatment of patients with active psoriatic arthritis and indi-
cations for anti-TNF agents with 25 mg etanercept SC twice 
per week over 12 weeks increased the PsARC response rates 
by 64% (NNT: 2) and the ACR20 response rates by 60% (NNT: 
2), reduced the number of affected joints by 53-70%, and in-
creased the functional response (disability index score) by 
29% (NNT: 3)45(A).
Patients with active psoriatic arthritis and inadequate 
response to NSAIDs were treated with 25 mg etanercept SC 
twice per week over 24 weeks. At week 12, the ACR20 re-
sponse rate increased 44% (NNT: 2), and the PsARC response 
rate increased 47% (NNT: 2). At week 24, functional capacity 
improvement (HAQ) increased 48% (NNT: 2)44(A). |Within 12 
months, the ACR20 and PsARC response rates were 64% and 
84%, respectively, and were thus similar to the values at week 
1253 (A). The patients treated with etanercept exhibited an in-
crease of 47.2% in improvement measured by HAQ-DI at week 
24, and 41.2% of the patients exhibited full response after 48 
weeks54(B).
Adalimumab
In adults with moderate to severe active psoriatic arthritis, 
treatment with adalimumab resulted in a 44% increase in 
the ACR20 response rate at week 12 (NNT: 2). At week 24, the 
ACR20 response rate increased by 42% (NNT: 2). In patients 
treated with adalimumab, the response as measured by 
PsARC improved by 36% at week 12 (NNT: 3) and by 37% at 
week 24 (NNT: 3)46(B).
In patients using adalimumab, the ACR20, ACR50, and 
ACR70 response rates were 56%, 44%, and 30%, respectively, 
at week 48. The PASI50, PASI75, PASI90, and PASI100 response 
rates were 67%, 58%, 46%, and 33%, respectively55(B).
Relative to the quality of life and function measured by 
the Dermatology Life Quality Index (DLQI), the Functional 
Assessment of Chronic Illness Therapy – Fatigue Scale (FAC-
IT-Fatigue), the HAQ-DI, the Minimum Clinically Important 
Difference (MCID), the Physical Component Summary Score 
(PCS), and the SF-36, the patients treated with adalimumab 
for 24 weeks exhibited the following results: 23.6% achieved 
the MCID in HAQ-DI (≥ -0.3 point change from baseline) (NNT: 
4); 20.9% achieved full resolution according to HAQ-DI (NNT: 
5); 31.6% achieved the MCID in SF-36 (≥ 5 points) (NNT: 3); 
31.6% achieved the MCID in FACIT (≥ 4 points) (NNT: 3); 31.3% 
achieved the MCID in DLQI (≥ -5 points); and 38.6% achieved 
full resolution according to DLQI (NNT: 3)56(B).
The percentages of patients who achieved responses ac-
cording to ACR20, ACR50, ACR70, and PsARC after two years 
were 57.3%, 42.7%, 29.9%, and 63.5%, respectively; these rates 
are similar to those found at week 48. The percentage of pa-
tients who achieved a full response (HAQ-DI) was 38.5%, and 
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the percentages of patients who achieved the MCID in HAQ-
DI, SF-36, FACIT–F, and DLQI were 47.6%, 50.0%, 76.7%, and 
56.3%, respectively; these values are also similar to those ob-
served at week 4857(B).
In patients with moderate to severe active psoriatic ar-
thritis, treatment with 40 mg adalimumab in alternate weeks 
over 12 weeks increased the ACR20, ACR50, ACR70 response 
rates by 23% (NNT: 4), 23% (NNT: 4), and 14% (NNT: 7), respec-
tively. The global activity of disease exhibited reduction, and 
the physical function (HAQ-DI) improved. The response was 
the same with or without combination of adalimumab with 
NSAIDs or corticoids. The (PsARC) response rate increased 
by 27% (NNT: 4), and scores of dactylitis and enthesitis 
decreased47(A).
The ACR20/50/70 response rates were 65%, 43%, and 27%, 
respectively, and that of PsARC was 75%, similar to that found 
at week 1247(A).
Golimumab
Patients with active psoriatic arthritis and inadequate re-
sponse to DMARDs or NSAIDs who were treated with golim-
umab (50 or 100 mg) every four weeks over 20 weeks exhibited 
increased ACR20 response rates of 42% and 36%, respectively, 
at week 14, independently of combination with methotrex-
ate. At week 14, the patients treated with golimumab at either 
dose also exhibited a 50% increase in (PsARC) response (NNT: 
2) and a 40% increase in EULAR (DAS-28) response48(A).
Recommendation 8
The effi cacy of various anti-TNF drugs (infl iximab, etanercept, 
adalimumab, and golimumab) relative to the treatment of pa-
tients with psoriatic arthritis does not differ, especially when 
response measures ACR20, PsARC, and HAQ are considered.
9. Does the safety of various anti-TNF drugs differ 
in patients with psoriatic arthritis?
Infl iximab
The number of adverse events did not increase when infl iximab 
was used. The most common adverse events were headache, 
bronchitis, respiratory infections, rhinitis, and skin rash42(A).
The number of adverse events, severe adverse events, and 
infections did not increase in patients treated with infl iximab 
(5 mg/kg at weeks 0, 2, 6, 14, and 22) compared to untreated 
patients. The proportion of instances of loss of adherence to 
treatment due to adverse events, including increased liver 
enzyme levels, was 4%. The most common adverse events 
were respiratory infection and headache; cancer may also 
occur43(A).
Etanercept
The most common adverse event occurring in patients with 
psoriatic arthritis using 25 mg etanercept SC twice per week 
over 12 weeks was respiratory infection45(A).
Patients with psoriatic arthritis and inadequate response 
to NSAIDs may be treated with 25 mg etanercept SC twice 
per week over 24 weeks combined or not with methotrex-
ate. Adverse events may occur, including chest pain, kidney 
stones, syncope, and multiple sclerosis. The number of ad-
verse events was not greater than in untreated patients. Most 
adverse events were moderate, and the most common event 
in up to two years of follow up was respiratory infection44,53(A).
Adalimumab
At week 24 of treatment, adalimumab did not result in an in-
crease in the number of adverse effects (respiratory infection, 
hypertension, and headache) compared to untreated patients. 
Severe adverse events included arthrodesis, seizures, viral 
meningitis, kidney stones, pancreatitis, thrombocytopenia, 
and increased liver enzymes, any of which might lead to dis-
continuation of treatment46 (B). Adalimumab was shown to be 
safe at week 4855(B).
The rate of adverse events in patients treated with adalim-
umab did not differ at two years compared to assessment at 
one year. Approximately 91.6% of the patients exhibited one 
adverse event, and 16.8% of them exhibited at least one se-
vere adverse event. The most common adverse events were 
gallstones, myocardial infarction, appendicitis, urinary tract 
infection, osteoarthritis, seizures, kidney stones, tuberculosis, 
and lymphoma; approximately 6.7% of the patients discontin-
ued treatment56(B).
Adverse events at week 12 were mild in 26.7% of the pa-
tients, and most events were of moderate severity47(A). In-
fection decreased by 15.1%, and no cases of tuberculosis, 
granulomatosis, demyelination, lupus, heart failure, or can-
cer occurred. At week 24, adverse events affected 54.6% of 
the patients. These events were severe in 3.1% and led to dis-
continuation in 6.2%. Other described adverse events include 
cough, nasopharyngitis, increased liver enzymes, lymphoma, 
and cancer47(A).
Table 1 - Comparison of the NNT in various anti-TNF drugs used in the treatment of psoriatic arthritis.
Drugs Outcomes (NNT)
ACR20 ACR50 ACR70 PsARC HAQ DAS 28 Enthesitis DLQI Dactylitis
Adalimumab 2 3 4 3
Etanercept 2 2 3
Golimumab 2 2 2
Infl iximab 2 2 3 2 3 2 6 2
NNT, number needed to treat; ACR, American College of Rheumatology Responders Index, PsARC, Psoriatic Arthritis Response Criteria; HAQ, 
Health Assessment Questionnaire; DAS-28, Disease Activity Score in 28 joints; DLQI, Dermatology Life Quality Index.
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Golimumab
At week 14, the most common adverse events observed in pa-
tients with active psoriatic arthritis and inadequate response 
to DMARDs or NSAIDs combined or not with methotrexate 
who were treated with 50 or 100 mg golimumab every four 
weeks over 20 weeks were nasopharyngitis and respiratory 
infection. Infections occurred most frequently at higher dos-
es. Approximately 3% of the instances of discontinuation of 
treatment were due to adverse events. Liver enzyme levels in-
creased 18-24% and 13-34% in the patients who used 50 and 
100 mg golimumab, respectively. Cancer and tuberculosis may 
occur and require treatment48(A).
Recommendation 9
Although it is diffi cult to quantify the occurrence of adverse 
effects, there are no signifi cant differences in the safety pro-
fi les of the various anti-TNF drugs used in the treatment of 
psoriatic arthritis. 
10. Is anti-TNF therapy able to reduce structural 
damage in patients with psoriatic arthritis?
Infl iximab
Use of infl iximab (5 mg/kg) at weeks 0, 2, and 6 and then every 
eight weeks until week 54 in patients with active psoriatic ar-
thritis was assessed with respect to erosions and joint space 
narrowing on hand and foot x-rays by means of the modifi ed 
Sharp/van der Heijde score. Treated patients showed less ra-
diological progression at weeks 24 and 54 compared to un-
treated patients. After two years of follow up, the radiological 
progression in the treated patients was signifi cantly lower 
than expected, and the adverse events remained within the 
range estimated in the fi rst stage of treatment51,57(B).
Patients with active psoriatic arthritis treated with 5 mg/
kg infl iximab at weeks 0, 2, 6, and 14 and then every eight 
weeks until week 50, as well as patients treated with the 
same dose at weeks 16, 18, and 22 and then every eight 
weeks until week 50, did not exhibit deterioration of radio-
logical structural signs or progression of disease as mea-
sured by the Sharp/van der Heijde score in 85% and 84% of 
cases, respectively58(B).
Etanercept
After 12 months of follow up, the radiological progression 
of disease exhibited a reduction of an average of –1.03 units 
in the Sharp score following use of etanercept. Combination 
with methotrexate did not change the results44(A). Radiologi-
cal progression was reduced corresponding to −1.38 unit in 
the total Sharp score after two years of follow up53(A).
Adalimumab
Treatment with adalimumab induced signifi cant inhibition 
of structural changes on radiographs. The average change in 
the total Sharp score from baseline to week 24 was 0.2 in the 
patients treated with adalimumab versus 1.0 in untreated 
patients46(B).
Signifi cant differences were also found in the erosion 
score. An average change of 0.0 was observed in the patients 
treated with adalimumab versus a change of 0.6 in patients 
who were not given treatment over the 24-week period. The 
score of joint space narrowing showed an average change of 
0.2 in patients treated with adalimumab versus 0.4 in untreat-
ed patients over the 24-week period46(B).
The changes in the Sharp score were 0.1 unit on average. 
The clinical and radiological responses were independent of 
combination with methotrexate55(B). 
After two years of treatment with 40 mg adalimumab on 
alternate weeks, 79.1% of patients exhibited reduction or no 
change in the Sharp score, similar to the results at weeks 24 
and 48. Of the patients who had not shown radiological pro-
gression at week 48, 84.3% continued to demonstrate no ra-
diological progression56(B).
Assessment by magnetic resonance imaging of patients 
with active psoriatic arthritis without history of infections, se-
vere disease, or demyelination and no previous use of anti-TNF 
drugs who were treated with 40 mg adalimumab on alternate 
weeks over 24 weeks showed 65% improvement in bone mar-
row swelling, no improvement in erosion score, 3% improve-
ment in synovitis score, and 44% reduction in joint swelling59(B).
Recommendation 10
Use of anti-TNF drugs in the treatment of psoriatic arthritis 
reduced the radiological progression of the disease, especially 
as measured by the Sharp score in patients who were moni-
tored for up to two years.
11. Should conventional drugs such as 
methotrexate, lefl unomide, and cyclosporine be 
used concomitantly with anti-TNF drugs?
Combination with DMARDs such as methotrexate, lefl uno-
mide, sulfasalazine, hydroxychloroquine, intramuscular gold, 
penicillamine, or azathioprine did not modify the outcomes 
in patients with psoriatic arthritis who were treated with 5 
mg/kg infl iximab42(A). 
Treatment of patients with active psoriatic arthritis and 
indication for anti-TNF drugs with 25 mg etanercept SC twice 
per week over 12 weeks combined or not combined with 
methotrexate increased the PsARC and ACR20 response45(A).
Patients with psoriatic arthritis treated with etanercept 
(25 mg twice per week) alone or combined with methotrexate 
(10-15 mg per week) exhibited similar survival rates after fi ve 
years60(B).
ACR20, ACR50, and ACR70 responses did not differ in pa-
tients treated with adalimumab alone or in combination with 
methotrexate46(B).
The response of patients with moderate to severe active 
psoriatic arthritis to treatment with 40 mg adalimumab on al-
ternate weeks over 12 weeks alone or combined with metho-
trexate or DMARDs (except for cyclosporine) was similar47(A).
Patients with active psoriatic arthritis and inadequate 
response to DMARDs or NSAIDs treated with 50 or 100 mg 
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golimumab every four weeks over 20 weeks exhibited in-
creased ACR20 response independently of combination with 
methotrexate48(A).
Treatment of patients with psoriatic arthritis over 12 
months with cyclosporine (2.5-3.75 mg/kg/day) and adalim-
umab (40 mg on alternate weeks) resulted in similar PsARC 
responses in patients treated with adalimumab alone. How-
ever, the ACR50 response rates were higher (87%) with the 
combination compared to adalimumab alone (69%). There 
was also reduction in the combination of adalimumab doses 
(10%)35(B).
Recommendation 11
The use of combinations of DMARDs such as methotrexate, 
cyclosporine, sulfasalazine, and lefl unomide with anti-TNF 
drugs (infl iximab, etanercept, adalimumab, golimumab) does 
not produce clinical results that differ from those obtained 
with the use of anti-TNF drugs alone in psoriatic arthritis. 
12. What is the evidence that supports switching 
anti-TNF drugs in patients with psoriatic 
arthritis?
Between 25% and 33% of patients with psoriatic arthritis dis-
continue the use of the fi rst anti-TNF drug after one year of 
treatment, usually due to the ineffi cacy of treatment or to ad-
verse events. Ineffi cacy is cited as a cause increasingly often 
as treatment progresses, while adverse events are cited less 
often over time. No clinically signifi cant difference in pain or 
functional (HAQ) outcome was found after treatment with the 
fi rst, second, and third anti-TNF drugs used61(B).
Approximately 33% of patients with psoriatic arthritis who 
were treated with anti-TNF drugs for periods of 6-70 months 
did not exhibit adequate response (61% due to lack of effi cacy, 
25% due to adverse events, and 14% due to loss of effi cacy 
over time). Of the patients who switched to a second anti-TNF 
drug due to lack of effi cacy, 92% exhibited adequate response, 
as did 60% of the patients who switched to a second anti-
TNF drug due to adverse events and 50% of the patients who 
switched to a third anti-TNF drug. Approximately 70% of the 
patients who switched to a second or third anti-TNF drug due 
to loss of effi cacy over time exhibited adequate response62(B). 
Following the use of 25 mg etanercept twice per week over 
12 weeks and then 50 mg etanercept twice per week, 45.8% of 
patients with psoriatic arthritis who were previously treated 
with infl iximab achieved PASI50, and 29.2% achieved PASI75 
at week 24. Of the patients without previous use of biologi-
cal agents, 92.3% and 73.8% achieved PASI50 and PASI75, 
respectively63(B).
Of patients who completed 12 months of treatment, 75.5% 
continued the fi rst anti-TNF drug, while 9.5% discontinued it 
due to ineffi cacy, 10.0% discontinued it due to adverse events, 
and 5.0% discontinued it for other reasons. The percentage of 
patients who maintained treatment with the fi rst anti-TNF 
(infl iximab, etanercept, or adalimumab) over the fi rst and sec-
ond years were 92% and 70%, respectively, and the percentage 
who maintained the fi rst anti-TNF drug to which they were 
switched over the fi rst and second years were 74% and 66%, 
respectively. One of the predictors of discontinuation and 
change in treatment was use of infl iximab instead of etaner-
cept [Hazard ratio (HR) = 2.8 after one year]64(B).
Approximately 97% of patients with psoriatic arthritis who 
were treated with a fi rst biological agent (infl iximab, etaner-
cept, or adalimumab) attained clinical response at week 12, 
and 90% of patients who required switching the anti-TNF 
drug achieved signifi cant response. Approximately 40% of the 
patients who required switching due to lack of response re-
sponded to the second-line agent, and half responded to the 
third course of treatment65(B).
Approximately 67% of patients with psoriatic arthritis 
switched from infl iximab to etanercept. After three months 
of treatment with etanercept, the proportion of patients who 
achieved PsARC response increased from 10-70% (NNT: 2), and 
the HAQ score decreased. Approximately 46% of patients with 
psoriatic arthritis switched from etanercept to adalimumab. 
After three months of treatment with adalimumab, the pro-
portion of patients who achieved PsARC response increased 
from 14.3-57.1% (NNT: 2)66(B).
Patients with psoriatic arthritis using anti-TNF drugs (in-
fl iximab, etanercept, or adalimumab) exhibited 87% adher-
ence/response, and the response of patients who switched 
to a second anti-TNF drug was 81%. The rate of response/
adherence was better among patients who switched to the 
second anti-TNF drug due to adverse events (HR for discon-
tinuation = 0.55) and among patients treated with infl iximab 
(HR= 3.22)67(B).
Recommendation 12 
Switching anti-TNF drugs in patients with psoriatic arthritis 
exhibiting adverse events or inadequate response is usually 
met by a satisfactory therapeutic response.
13. How long should an anti-TNF drug be used in 
the treatment of patients with psoriatic arthritis?
In patients with psoriatic arthritis treated with etanercept SC 
(50 mg twice per week over 12 weeks followed by 25 mg twice 
per week), the clinical response assessed by means of DAS 28, 
pain VAS, and PASI was as follows68(B): 
• After 48 weeks of treatment: 76.8% reduction of pain (VAS); 
44% reduction of the DAS28 score; 83% reduction of the 
PASI50 score, 78% reduction of the PASI75 score, and 43% 
reduction of the PASI90 score, with average PASI of 70%;
• After 96 weeks of treatment: 89.6% reduction of pain (VAS); 
57% reduction in the DAS28 score; 87% reduction of the 
PASI50 score, 81% reduction of the PASI75 score, and 65% 
reduction of the PASI90 score, with average PASI of 82%;
• After 144 weeks of treatment: 94.7% reduction of pain 
(VAS); 67% reduction of the DAS28 score; 96% reduction of 
the PASI50 score, 92% reduction of the PASI75 score, and 
66% reduction of the PASI90 score, with average PASI of 
74%.
The ACR20 responses of patients with psoriatic arthritis 
treated with infl iximab at three months, one year, and two 
years were 79%, 61%, and 80%, respectively; the correspond-
ing results for patients treated with etanercept were 76%, 
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80%, and 90%. The ACR50 responses of patients with psoriatic 
arthritis treated with infl iximab at three months, one year, 
and two years were 64%, 39%, and 40%, respectively; the cor-
responding results for patients treated with etanercept were 
49%, 65%, and 68%69(B).
After fi ve years of treatment with infl iximab (5 mg/kg intra-
venously) at weeks 0, 2, and 6 and then every eight weeks, the 
percentage of patients who achieved PsARC was 60%, PASI70 
was 66.7%, PASI90 was 63.3%, and ACR50 was 56.7%. In pa-
tients treated with etanercept (25 mg SC) twice per week, the 
percentage who achieved PsARC was 64%, PASI70 and PASI90 
was 68%, and ACR50 was 56%. The percentages of response to 
treatment with adalimumab (40 mg SC) on alternate weeks 
were PsARC 56%, PASI70 58%, PASI90 50%, and ACR50 50%. 
At the end of treatment, the survival rate of patients treated 
with infl iximab was 56.7%, etanercept was 76%, and adalim-
umab was 50%70(B). 
Episodes of remission in patients with psoriatic arthritis 
treated with anti-TNF increased by 17% after six years of fol-
low up; the average length of remission was 13 ± 9.4 months. 
The frequency of remission during the period without treat-
ment increased 60% in patients treated with anti-TNF drugs 
compared to the frequency of remission in patients treated 
with methotrexate. The length of remission following discon-
tinuation of treatment was 12 ± 2.4 months71(B).
The percentages of patients treated with adalimumab who 
achieved ACR20, ACR50, ACR70, and PsARC responses after 
two years were 57.3%, 42.7%, 29.9%, and 63.5%, respectively, 
similar to the results at week 48. Full response (HAQ-DI) was 
achieved by 38.5% of the patients, and the percentage of pa-
tients who achieved MCID in HAQ-DI, SF-36, FACIT-F, and DLQI 
was 47.6%, 50.0%, 76.7%, and 56.3%, respectively, also similar 
to the results at week 4856(B).
The percentage of patients with active psoriatic arthritis 
treated with 25 mg etanercept SC twice per week over two 
weeks who achieved ACR20 increased by 44% (NNT: 2), and 
the percentage who achieved PsARC increased by 47% (NNT: 
2) at week 12. At week 24, functional capacity improvement 
(HAQ) increased by 48% (NNT: 2)50(B). After 12 months, the 
ACR20 and PsARC response rates were 64% and 84%, respec-
tively, similar to the results at week 1251(B). Patients treated 
with etanercept exhibited 47.2% improvement as measured 
by HAQ-DI at week 24, and 41.2% of the patients exhibited full 
response at week 4852(A).
The proportion of patients with psoriatic arthritis treated 
with infl iximab (5 mg/kg) on weeks 0, 2, 5, 14, and 22 who 
achieved ACR20 at week 14 (48% - NNT: 2) and at week 24 (38% 
- NNT: 2) was higher. At week 14, 33% of the patients treated 
with infl iximab achieved ACR50 response (NNT: 3), and 14% 
achieved ACR70 (NNT: 7)7(B). These results persisted until 
week 5450(B). After two years of follow up, the ACR20, ACR50, 
and ACR70 response rates were 45% and 35%, respectively51(B).
Recommendation 13
Treatment of psoriatic arthritis with anti-TNF drugs for 
more than six years shows stability of the effi cacy and safety 
achieved in the fi rst year. Treatment might be discontinued 
when signs of remission appear; on average, remission lasts 
for 12 months. 
14. Is there evidence that supports the use of 
biological agents with other mechanisms of 
action in psoriatic arthritis?
Ustekinumab 
Treatment of patients with active psoriatic arthritis with 90 
mg ustekinumab every week over four weeks increased the 
percentage of ACR20, ACR50, and ACR70 response by 28% 
(NNT: 4), 18% (NNT: 6), and 11% (NNT: 9), respectively, at week 
12. However, at weeks 24, 28, and 36, the rates of clinical re-
sponse did not increase72(B). 
After 12 weeks of treatment with ustekinumab, patients 
with psoriatic arthritis exhibited 88% reduction in HAQ-DI, 
99% reduction in DLQI, and the number of patients with score 
0 or one in DLQI increased by 53%73(B). Ustekinumab may be 
associated with a favourable response of the skin component 
of disease regardless of the presence of joint response. 
Abatacept
After six months of treatment with abatacept at a dose of 
30/10 mg/kg, the percentage of patients who achieved ACR20 
increased by 23%; this percentage increased by 29% at a dose 
of 10 mg/kg. The ACR50 and ACR70 response rates were 25% 
and 13%, respectively, at 10 mg/kg. The ACR20 response rate 
at a dose of 10 mg/kg increased by 25% in patients who had 
never used anti-TNF drugs (NNT: 4)74(B).
Recommendation 14
Currently, there is no evidence supporting the use of non-
anti-TNF biological agents in the treatment of patients with 
psoriatic arthritis. 
15. Is there any evidence for the effi cacy of 
the medications used in the treatment of skin 
psoriasis with respect to the articular and 
periarticular manifestations of psoriatic arthritis? 
In patients with moderate to severe stable plaque psoriasis 
affecting at least 10% of the body surface and in patients with 
active psoriatic arthritis, treatment with etanercept (50 or 100 
mg per week over 12 weeks followed by 50 mg over a further 
12 weeks) led to 62%-70% skin improvement as measured by 
PASI75, to 70%, 50%, and 35% improvement in arthritis re-
sponse measured by ACR20, ACR50, and ACR70, respectively, 
and to reduction in dactylitis and enthesitis scores. Analysis 
of combined outcomes [Euro-Qol (EQ-5D®), PASI, and ACR50] 
showed that treatment benefi ted 31% of patients75,76(A).
Most of the agents used in the treatment of psoriasis 
(adalimumab, infl iximab, etanercept, methotrexate, and cy-
closporine) are also used in the treatment of psoriatic arthri-
tis. These biological agents are the medications with the best 
effi cacy and fewest adverse events, and they produce con-
comitant skin and joint improvement. Patients with moder-
ate to severe psoriasis and history of psoriatic arthritis who 
were treated with adalimumab exhibited 83% reduction in the 
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pain VAS at week 16. The concomitant (PASI and ACR20) re-
sponse increased by 99% at week 1677(A).
Recommendation 15 
Concomitant or combined skin and joint responses are usu-
ally detected with treatments for psoriatic arthritis that em-
ploy anti-TNF agents. 
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Appendix
Question 1
What are the criteria on the basis of which an individual is 
considered to have psoriatic arthritis? 
(Arthritis, Psoriatic OR Psoriasis Arthropathica OR Ar-
thritic Psoriasis) AND (sensitiv*[Title/Abstract] OR sen-
sitivity and specifi city[MeSH Terms] OR diagnos*[Title/
Abstract] OR diagnosis[MeSH:noexp] OR diagnostic* 
[MeSH:noexp] OR diagnosis, differential[MeSH:noexp] OR 
diagnosis[Subheading:noexp])
Question 2
Are there correlations among skin, nail, and joint disease ac-
tivity in psoriatic arthritis?
(Arthritis, Psoriatic OR Psoriasis Arthropathica OR Arthritic 
Psoriasis) AND (Skin OR joints OR nails OR dactylitis) AND 
(sensitiv*[Title/Abstract] OR sensitivity and specifi city[MeSH 
Terms] OR diagnos*[Title/Abstract] OR diagnosis[MeSH:noexp] 
OR diagnostic*[MeSH:noexp] OR diagnosis, 
differential[MeSH:noexp] OR diagnosis[Subheading:noexp])
Question 3
What are the comorbidities most often associated with pso-
riatic arthritis?
(Arthritis, Psoriatic OR Psoriasis Arthropathica OR Ar-
thritic Psoriasis) AND (Comorbidit* OR Complication*) AND 
((sensitiv*[Title/Abstract] OR sensitivity and specifi city[MeSH 
Terms] OR diagnos*[Title/Abstract] OR diagnosis[MeSH:noexp] 
OR diagnostic * [MeSH:noexp] OR diagnosis, 
differential[MeSH:noexp] OR diagnosis[Subheading:noexp]) 
OR (risk*[Title/Abstract] OR risk*[MeSH:noexp] OR risk 
*[MeSH:noexp] OR cohort studies[MeSH Terms] OR group*[Text 
Word]))
Question 4
What is the evidence regarding the use of corticosteroids in 
patients with psoriatic arthritis?
(Arthritis, Psoriatic OR Psoriasis Arthropathica OR Arthrit-
ic Psoriasis) AND (Steroids OR Androstanes OR Androstanols 
OR Androstenes OR Cardanolides OR Cardenolides OR Car-
diac Glycosides OR Sterols OR Cyclosteroids OR Estranes 
OR Estrenes OR Gonanes OR Homosteroids OR Testolactone 
OR Hydroxysteroids OR Ketosteroids OR 17-Ketosteroids OR 
Norsteroids OR Norandrostanes OR Norpregnanes OR Preg-
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nanes OR Pregnadienes OR Pregnanediol OR Pregnanedio-
nes OR Pregnanetriol OR Pregnanolone OR Pregnatrienes OR 
Pregnenes OR Tetrahydrocortisol OR Sapogenins OR Secoste-
roids OR Beclomethasone OR Chlormadinone OR Cyproter-
one OR Fluorinated OR Betamethasone OR Dexamethasone 
OR Flumethasone OR Fluocinolone OR Fluocortolone OR 
Fluorometholone OR Fluoxymesterone OR Fluprednisolone 
OR Flurandrenolone OR Flurogestone OR Paramethasone OR 
Triamcinolone OR Prednisolone OR Hydrocortisone OR cor-
ticosteroids OR Mineralocorticoids OR Glucocorticoids OR 
Hydroxycorticosteroids)
Question 5
What is the evidence regarding the use of non-steroidal anti-
infl ammatory drugs (NSAIDs) in patients with psoriatic ar-
thritis?
(Arthritis, Psoriatic OR Psoriasis Arthropathica OR Arthritic 
Psoriasis) AND (Anti-Infl ammatory Agents OR Cyclooxygen-
ase 2 OR COX-2 OR rofecoxib OR Ibuprofen OR celecoxib OR 
Naproxen OR Acetaminophen OR NSAID OR paracetamol 
OR parecoxib OR diclofenac OR aspirin OR meloxicam OR 
acetylsalicylic OR piroxicam) AND (randomised controlled 
trial[Publication Type] OR (randomised[Title/Abstract] AND 
controlled[Title/Abstract] AND trial[Title/Abstract]))
Question 6
What is the evidence regarding the use of the conventional 
drugs methotrexate, cyclosporine, lefl unomide, and sulfasala-
zine in patients with psoriatic arthritis?
(Arthritis, Psoriatic OR Psoriasis Arthropathica OR Arthritic 
Psoriasis) AND (methotrexate OR lefl unomide OR sulfasala-
zine OR gold sodium OR hydroxychloroquine OR ciclosporin) 
AND ((clinical[Title/Abstract] AND trial[Title/Abstract]) OR 
clinical trials[MeSH Terms] OR clinical trial[Publication Type] 
OR random*[Title/Abstract] OR random allocation[MeSH 
Terms] OR therapeutic use[MeSH Subheading])
Question 7
What are the indications for the use of anti-tumour necrosis 
factor (TNF) agents in psoriatic arthritis?
(Arthritis, Psoriatic OR Psoriasis Arthropathica OR Ar-
thritic Psoriasis) AND (Tumor Necrosis Factor-alpha OR go-
limumab OR infl iximab OR adalimumab OR etanercept) 
AND (randomised controlled trial[Publication Type] OR 
(randomised[Title/Abstract] AND controlled[Title/Abstract] 
AND trial[Title/Abstract]))
Question 8
Does the effi cacy of the various anti-TNF drugs differ in pa-
tients with psoriatic arthritis?
(Arthritis, Psoriatic OR Psoriasis Arthropathica OR Ar-
thritic Psoriasis) AND (Tumour Necrosis Factor-alpha OR 
golimumab OR infl iximab OR adalimumab OR etanercept) 
AND (randomised controlled trial[Publication Type] OR 
(randomised[Title/Abstract] AND controlled[Title/Abstract] 
AND trial[Title/Abstract]))
Question 9
Does the safety of various anti-TNF drugs differ in patients 
with psoriatic arthritis? 
(Arthritis, Psoriatic OR Psoriasis Arthropathica OR Arthritic 
Psoriasis) AND (Tumour Necrosis Factor-alpha OR golimumab 
OR infl iximab OR adalimumab OR etanercept) AND (radio-
graph* OR damage OR structur* OR joint OR imag*)
Question 10
Is anti-TNF therapy able to reduce structural damage in pa-
tients with psoriatic arthritis? 
(Arthritis, Psoriatic OR Psoriasis Arthropathica OR Arthritic 
Psoriasis) AND (Tumour Necrosis Factor-alpha OR golimumab 
OR infl iximab OR adalimumab OR etanercept) AND (radio-
graph* OR damage OR structur* OR joint OR imag*)
Question 11
Should conventional drugs such as methotrexate, lefl unomide, 
and cyclosporine be used concomitantly with anti-TNF drugs?
(Arthritis, Psoriatic OR Psoriasis Arthropathica OR Arthritic 
Psoriasis) AND (Tumour Necrosis Factor-alpha OR golimumab 
OR infl iximab OR adalimumab OR etanercept) AND (metho-
trexate OR lefl unomide OR sulfasalazine OR gold sodium OR 
hydroxychloroquine OR ciclosporin)
Question 12
What is the evidence that supports switching anti-TNF drugs 
in patients with psoriatic arthritis?
(Arthritis, Psoriatic OR Psoriasis Arthropathica OR Arthritic 
Psoriasis) AND switch*)
Question 13
How long should an anti-TNF drug be used in the treatment of 
patients with psoriatic arthritis? 
(Arthritis, Psoriatic OR Psoriasis Arthropathica OR Arthritic 
Psoriasis) AND (Time OR follow-up OR cohort)
Question 14
Is there evidence that supports the use of biological agents 
exhibiting other mechanisms of action in psoriatic arthritis?
(Arthritis, Psoriatic OR Psoriasis Arthropathica OR Arthritic 
Psoriasis) AND (rituximab OR tocilizumab OR abatacept OR 
Antibodies, Monoclonal) AND ((clinical[Title/Abstract] AND 
trial[Title/Abstract]) OR clinical trials[MeSH Terms] OR clinical 
trial[Publication Type] OR random*[Title/Abstract] OR random 
allocation[MeSH Terms] OR therapeutic use[MeSH Subheading])
Question 15
Is there evidence for the effi cacy of the medications used in 
the treatment of skin psoriasis relative to the articular and 
periarticular manifestations of psoriatic arthritis? 
“Arthritis, Psoriatic”[Mesh] AND “Psoriasis”[Mesh] AND 
((clinical[Title/Abstract] AND trial[Title/Abstract]) OR clini-
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cal trials[MeSH Terms] OR clinical trial[Publication Type] OR 
random*[Title/Abstract] OR random allocation[MeSH Terms] 
OR therapeutic use[MeSH Subheading])
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